Compare
Nexentis Technologies Inc. vs Quoin Pharmaceuticals Ltd. vs Evofem Biosciences, Inc. vs Abvc Biopharma, Inc.
| Latest fiscal year | Nexentis Technologies Inc. NXTS | Quoin Pharmaceuticals Ltd. QNRX | Evofem Biosciences, Inc. EVFM | Abvc Biopharma, Inc. ABVC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $20.18M | $296.0K |
| Revenue growth (YoY) | n/a | n/a | +4.2% | -41.9% |
| Gross margin | n/a | n/a | 77.1% (computed) | n/a |
| Operating margin | n/a | n/a | 16.7% | n/m |
| Net margin | n/a | n/a | 1.9% | n/m |
| Net income | -$4.00M | -$15.80M | $391.0K | -$7.91M |
| EPS (Diluted) | -$8.61 | n/a | $0.00 | -$0.39 |
| Operating cash flow | -$3.81M | -$13.54M | -$1.99M | -$2.99M |
| Free cash flow | -$3.82M | n/a | -$2.00M | n/a |
| Cash & equivalents | $3.83M | $3.82M | $578.0K | $681.5K |
| Total assets | $20.41M | $20.39M | $20.27M | $21.06M |
| Total liabilities | $4.67M | $7.27M | $89.71M | $7.76M |
| Shareholders' equity | $16.01M | $13.12M | -$74.34M | $11.11M |
| Return on year-end equity | -25.0% | -120.5% | n/a | -71.2% |
| Shares outstanding | 2.77M | 52.44M | 126.69M | 25.05M |
Revenue, most recent five fiscal years
| Fiscal year | Nexentis Technologies Inc. | Quoin Pharmaceuticals Ltd. | Evofem Biosciences, Inc. | Abvc Biopharma, Inc. |
|---|---|---|---|---|
| Latest | $210.0K Ended 2024-12-31 | $0 Ended 2021-12-31 | $20.18M Ended 2025-12-31 | $296.0K Ended 2025-12-31 |
| 1 year earlier | $263.0K Ended 2023-12-31 | $0 Ended 2020-12-31 | $19.36M Ended 2024-12-31 | $509.6K Ended 2024-12-31 |
| 2 years earlier | $394.0K Ended 2022-12-31 | $0 Ended 2019-12-31 | $18.22M Ended 2023-12-31 | n/a |
| 3 years earlier | $438.1K Ended 2021-12-31 | n/a | $16.84M Ended 2022-12-31 | n/a |
| 4 years earlier | $232.3K Ended 2020-12-31 | n/a | $8.24M Ended 2021-12-31 | n/a |